Cancer – ADVL1416: Phase 2 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor 2 Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
Condition or Therapy:
Pediatric solid tumor
What is the goal of this study?
The goal of this study is to to learn how patients with solid tumors react to ramucirumab.
Who can join the study?
This study might be a good fit for children and young adults who:
- Are 21 monhts to 21 years old
- Have a recurrent or refractory non-CNS or CNS solid tumors
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or send us an email.